Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29052034 | 0.85 | PIK3CA (0.33) | AR | |
| SCHEMBL25392435 | 0.78 | WDR5 (0.39) | — | |
| SCHEMBL24826178 | 0.76 | PIM1 (0.33) | — | |
| SCHEMBL14926117 | 0.76 | KIT (0.33) | — | |
| SCHEMBL24826177 | 0.76 | — | — | |
| SCHEMBL24501900 | 0.72 | CPB2 (0.34) | — | |
| SCHEMBL24495989 | 0.72 | CCNT1 (0.32) | — | |
| SCHEMBL16972877 | 0.68 | ALPL (0.34) | AR | |
| SCHEMBL29593067 | 0.66 | CDK5 (0.46) | — | |
| SCHEMBL31591382 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117561061-A | Combination of 3- (imidazol-4-yl) -4- (amino) -benzenesulfonamide TEAD inhibitors with EGFR inhibitors and/or MEK inhibitors for the treatment of lung cancer | 医肯纳肿瘤学公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-4281073-A1 | COMBINATION OF A 3-(IMIDAZOL-4-YL)-4-(AMINO)-BENZENESULFONAMIDE TEAD INHIBITOR WITH AN EGFR INHIBITOR AND/OR MEK INHIBITOR FOR USE IN THE TREATMENT OF LUNG CANCER | Ikena Oncology, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2023-09-14 | — | — | US | disclosed |
| CN-116194455-A | Protein secretion inhibitor | 科智生命科学公司 | 2023-05-30 | — | — | CN | disclosed |
| WO-2022159986-A1 | COMBINATION OF A 3-(IMIDAZOL-4-YL)-4-(AMINO)-BENZENESULFONAMIDE TEAD INHIBITOR WITH AN EGFR INHIBITOR AND/OR MEK INHIBITOR FOR USE IN THE TREATMENT OF LUNG CANCER | Ikena Oncology, Inc. (US) | 2022-07-28 | — | — | WO | disclosed |
| WO-2022120353-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022120355-A1 | TEAD DEGRADERS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | AR 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.